Clinical Oncology Education

Navigating a New Frontier in Oncology: The Clinical Integration of Zolbetuximab for Advanced Gastric Cancer

• Clinical Oncology Education

Navigating a New Frontier in Oncology: The Clinical Integration of Zolbetuximab for Advanced Gastric Cancer

Asro June 4, 2026 0

The landscape of oncology is perpetually shifting, driven by the relentless pursuit of molecular targets that offer...

Read More Read more about Navigating a New Frontier in Oncology: The Clinical Integration of Zolbetuximab for Advanced Gastric Cancer

New Hope in Triple-Negative Breast Cancer: ASCENT-04 Trial Signals Potential Paradigm Shift in First-Line Treatment

• Clinical Oncology Education

New Hope in Triple-Negative Breast Cancer: ASCENT-04 Trial Signals Potential Paradigm Shift in First-Line Treatment

Ali Ikhwan June 3, 2026 0

By Oncology News Desk The landscape of metastatic triple-negative breast cancer (mTNBC) treatment is on the precipice...

Read More Read more about New Hope in Triple-Negative Breast Cancer: ASCENT-04 Trial Signals Potential Paradigm Shift in First-Line Treatment

Breakthrough in Liver Cancer Treatment: EMERALD-3 Trial Results Promise New Standard of Care

• Clinical Oncology Education

Breakthrough in Liver Cancer Treatment: EMERALD-3 Trial Results Promise New Standard of Care

Siti Muinah June 2, 2026 0

The landscape of liver cancer treatment is on the precipice of a significant evolution. New data from...

Read More Read more about Breakthrough in Liver Cancer Treatment: EMERALD-3 Trial Results Promise New Standard of Care

A New Dawn for Pancreatic Cancer: Daraxonrasib Nearly Doubles Survival in Landmark Phase 3 Trial

• Clinical Oncology Education

A New Dawn for Pancreatic Cancer: Daraxonrasib Nearly Doubles Survival in Landmark Phase 3 Trial

Azzam Bilal Chamdy June 1, 2026 0

In a development being hailed by the oncology community as a potential "landscape-changing" breakthrough, results from the...

Read More Read more about A New Dawn for Pancreatic Cancer: Daraxonrasib Nearly Doubles Survival in Landmark Phase 3 Trial

New Hope for High-Risk Lymphoma: Phase III frontMIND Trial Challenges Decades-Old Standard of Care

• Clinical Oncology Education

New Hope for High-Risk Lymphoma: Phase III frontMIND Trial Challenges Decades-Old Standard of Care

Muslim May 31, 2026 0

In a breakthrough that promises to reshape the therapeutic landscape for aggressive non-Hodgkin lymphomas, researchers have unveiled...

Read More Read more about New Hope for High-Risk Lymphoma: Phase III frontMIND Trial Challenges Decades-Old Standard of Care

Rethinking Breast Cancer Surgery: Landmark SENOMAC Trial Challenges Standard Axillary Procedures

• Clinical Oncology Education

Rethinking Breast Cancer Surgery: Landmark SENOMAC Trial Challenges Standard Axillary Procedures

Ali Ikhwan May 30, 2026 0

In a pivotal shift for breast cancer surgical oncology, findings from the Phase III SENOMAC clinical trial...

Read More Read more about Rethinking Breast Cancer Surgery: Landmark SENOMAC Trial Challenges Standard Axillary Procedures

Precision and Personalization: A Deep Dive into the ESMO Breast Cancer Congress 2026

• Clinical Oncology Education

Precision and Personalization: A Deep Dive into the ESMO Breast Cancer Congress 2026

Rifan Muazin May 30, 2026 0

The 2026 edition of the ESMO Breast Cancer Congress has concluded, leaving behind a clear roadmap for...

Read More Read more about Precision and Personalization: A Deep Dive into the ESMO Breast Cancer Congress 2026

Could Short-Term Fasting Improve Chemotherapy Outcomes in Ovarian Cancer? New Research Suggests Potential

• Clinical Oncology Education

Could Short-Term Fasting Improve Chemotherapy Outcomes in Ovarian Cancer? New Research Suggests Potential

Nila Kartika Wati May 30, 2026 0

A promising new pilot study from Italy, set to be presented at the 2026 American Society of...

Read More Read more about Could Short-Term Fasting Improve Chemotherapy Outcomes in Ovarian Cancer? New Research Suggests Potential

Landmark Oncology Breakthrough: GLP-1 Agonists Linked to Reduced Metastatic Risk in Obesity-Related Cancers

• Clinical Oncology Education

Landmark Oncology Breakthrough: GLP-1 Agonists Linked to Reduced Metastatic Risk in Obesity-Related Cancers

Azzam Bilal Chamdy May 30, 2026 0

As the global oncology community turns its collective attention toward Chicago for the 2024 American Society of...

Read More Read more about Landmark Oncology Breakthrough: GLP-1 Agonists Linked to Reduced Metastatic Risk in Obesity-Related Cancers

Precision and Persistence: Hematologic Oncology at the 2026 ASCO Annual Meeting

• Clinical Oncology Education

Precision and Persistence: Hematologic Oncology at the 2026 ASCO Annual Meeting

Basiran May 29, 2026 0

The 2026 Annual Meeting of the American Society of Clinical Oncology (ASCO) has served as a pivotal...

Read More Read more about Precision and Persistence: Hematologic Oncology at the 2026 ASCO Annual Meeting